Casdin Capital’s Zymeworks ZYME Stock Holding History

Casdin Capital’s Portfolio ZYME Stock Details ZYME Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-130,000	Closed	-$4.69M	–	47
2020 Q2	$4.69M	Buy	+130,000	New	+$4.79M	0.28%	40

Other funds holding ZYME

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

GPP

Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Casdin Capital's ZYME Position: Q3 2020 in Review

Casdin Capital sold out of Zymeworks (ZYME) in Q3 2020, closing a stake of 130,000 shares — an estimated $4.69M sold.

Casdin Capital first reported a position in ZYME in Q2 2020 and held it in 1 quarter. The position peaked at $4.69M in Q2 2020. 127 funds tracked by Wall St. Rank hold ZYME as of Q3 2020.

Casdin Capital reported no remaining Zymeworks position as of Q3 2020 after selling out during the quarter.
Casdin Capital sold 130,000 Zymeworks shares in Q3 2020, an estimated $4.69M.
Casdin Capital first reported a position in Zymeworks in Q2 2020 and held it in 1 quarter.
Casdin Capital's Zymeworks position peaked at $4.69M in Q2 2020.
127 funds tracked by Wall St. Rank held Zymeworks as of Q3 2020.

Based on Casdin Capital's 13F filing for Q3 2020, filed 16 Nov 2020.